Q: What is Uplizna used for?

Uplizna is used to treat neuromyelitis optica spectrum disorder .

Q: How does Uplizna work?

Targeting B Cells Uplizna is a monoclonal antibody designed to target a specific protein called CD19. This protein is found on the surface of B cells, which are white blood cells that are part of the immune system. How It Protects the Nervous System In patients with neuromyelitis optica spectrum disorder (NMOSD), the immune system incorrectly attacks the central nervous system, including the optic nerves and spinal cord. This attack is often driven by B cells that produce harmful antibodies. When Uplizna binds to the CD19 protein on these B cells, it causes the body to deplete or remove them from circulation. By reducing the number of these specific immune cells, the medication helps to: Lower the production of antibodies that cause inflammation and nerve damage. Decrease the likelihood of disease relapses or attacks. Limit the damage to the protective coating of the nerves. The exact way the drug works to improve the condition is through this targeted depletion of B cells, which calms the overactive immune response characteristic of NMOSD.

Q: What are the active ingredients in Uplizna?

The active ingredient in Uplizna is inebilizumab .

Q: What are the side effects of Uplizna?

Common side effects of Uplizna may include: infusion-related reactions headache upper respiratory tract infection and others Always consult with a healthcare professional about potential side effects.

Q: What is the dosage of Uplizna and how do I take it?

Administration Uplizna is given as an infusion into a vein (intravenous infusion) by a healthcare provider. The procedure typically takes place in a clinical setting such as a doctor's office, hospital, or infusion center. Dosing Schedule The treatment begins with two initial doses given a few weeks apart. After these starting doses, maintenance infusions are typically scheduled once every six months. Before the Infusion To help prevent infusion-related reactions, your healthcare provider will likely give you other medications before each treatment. These pre-medications may include: A corticosteroid An antihistamine A fever-reducing medication During and After the Infusion A healthcare professional will monitor you closely during the infusion and for a period of time afterward to check for any signs of a reaction. Missed Dose If you miss an appointment for your infusion, contact your healthcare provider immediately to reschedule. It is important to receive your doses as scheduled to manage your condition effectively.

Q: Is Uplizna safe during pregnancy and breastfeeding?

Pregnancy Data regarding the use of Uplizna in pregnant women are limited, and it is not yet known if the medication can cause fetal harm. Because Uplizna is a monoclonal antibody, it can cross the placenta, particularly during the second and third trimesters. This may lead to a reduction in B-cells (a type of white blood cell) in the newborn, which could temporarily affect the infant's immune system. Individuals who are able to become pregnant should use effective contraception during treatment and for at least 6 months after the final dose of Uplizna. Healthcare providers typically perform a pregnancy test before starting this medication to ensure the patient is not pregnant. Breastfeeding It is currently unknown whether Uplizna passes into human breast milk or if it has any effect on a breastfed infant or milk production. While many antibodies are known to be present in human milk, the specific risks associated with Uplizna are not established. Patients should discuss the potential benefits and risks of breastfeeding with their healthcare provider when considering this treatment.

Q: What is the FDA approval status of Uplizna?

FDA Approval History The U.S. Food and Drug Administration (FDA) approved Uplizna on June 11, 2020. It was the second treatment approved by the FDA for its specific indication and was developed by Horizon Therapeutics. Approved Indications Uplizna is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is a rare autoimmune disease that affects the central nervous system, primarily the optic nerves and spinal cord. Regulatory Designations During its clinical development, Uplizna received Orphan Drug designation from the FDA. This status is granted to drugs intended for the treatment of rare diseases or conditions that affect fewer than 200,000 people in the United States. Safety and Monitoring There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategy (REMS) programs required for Uplizna. However, the FDA-approved labeling requires healthcare providers to confirm the presence of AQP4 antibodies before initiating treatment, as the drug's efficacy has only been established in patients who are antibody-positive.

Question 1

What is Uplizna?

Accepted Answer

Uplizna is a monoclonal antibody that targets the CD19 protein found on the surface of B-lymphocytes. By binding to these specific immune cells, the medication triggers their removal from the circulation.

This depletion of B cells is the primary mechanism by which the therapy exerts its effects on the immune system. It is designed to reduce the number of these cells circulating throughout the body.

Question 2

What is Uplizna used for?

Accepted Answer

Uplizna is used to treat neuromyelitis optica spectrum disorder.

Question 3

How does Uplizna work?

Accepted Answer

Targeting B Cells

Uplizna is a monoclonal antibody designed to target a specific protein called CD19. This protein is found on the surface of B cells, which are white blood cells that are part of the immune system.

How It Protects the Nervous System

In patients with neuromyelitis optica spectrum disorder (NMOSD), the immune system incorrectly attacks the central nervous system, including the optic nerves and spinal cord. This attack is often driven by B cells that produce harmful antibodies.

When Uplizna binds to the CD19 protein on these B cells, it causes the body to deplete or remove them from circulation. By reducing the number of these specific immune cells, the medication helps to:

Lower the production of antibodies that cause inflammation and nerve damage.
Decrease the likelihood of disease relapses or attacks.
Limit the damage to the protective coating of the nerves.

The exact way the drug works to improve the condition is through this targeted depletion of B cells, which calms the overactive immune response characteristic of NMOSD.

Question 4

What are the active ingredients in Uplizna?

Accepted Answer

The active ingredient in Uplizna is inebilizumab.

Question 5

What are the side effects of Uplizna?

Accepted Answer

Common side effects of Uplizna may include:

infusion-related reactions
headache
upper respiratory tract infection
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Uplizna?

Accepted Answer

Uplizna belongs to the monoclonal antibody drug class.

Question 7

What is the dosage of Uplizna and how do I take it?

Accepted Answer

Administration

Uplizna is given as an infusion into a vein (intravenous infusion) by a healthcare provider. The procedure typically takes place in a clinical setting such as a doctor's office, hospital, or infusion center.

Dosing Schedule

The treatment begins with two initial doses given a few weeks apart. After these starting doses, maintenance infusions are typically scheduled once every six months.

Before the Infusion

To help prevent infusion-related reactions, your healthcare provider will likely give you other medications before each treatment. These pre-medications may include:

A corticosteroid
An antihistamine
A fever-reducing medication

During and After the Infusion

A healthcare professional will monitor you closely during the infusion and for a period of time afterward to check for any signs of a reaction.

Missed Dose

If you miss an appointment for your infusion, contact your healthcare provider immediately to reschedule. It is important to receive your doses as scheduled to manage your condition effectively.

Question 8

Is Uplizna safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Data regarding the use of Uplizna in pregnant women are limited, and it is not yet known if the medication can cause fetal harm. Because Uplizna is a monoclonal antibody, it can cross the placenta, particularly during the second and third trimesters. This may lead to a reduction in B-cells (a type of white blood cell) in the newborn, which could temporarily affect the infant's immune system.

Individuals who are able to become pregnant should use effective contraception during treatment and for at least 6 months after the final dose of Uplizna. Healthcare providers typically perform a pregnancy test before starting this medication to ensure the patient is not pregnant.

Breastfeeding

It is currently unknown whether Uplizna passes into human breast milk or if it has any effect on a breastfed infant or milk production. While many antibodies are known to be present in human milk, the specific risks associated with Uplizna are not established. Patients should discuss the potential benefits and risks of breastfeeding with their healthcare provider when considering this treatment.

Question 9

What forms and strengths does Uplizna come in?

Accepted Answer

Uplizna is supplied as a sterile, preservative-free solution in single-dose vials. This medication is intended for intravenous use and must be administered by a healthcare provider in a clinical setting.

The solution is typically clear to slightly opalescent and colorless to slightly yellow. Before administration, the medication is diluted into an infusion bag for delivery into a vein.

Question 10

What is the FDA approval status of Uplizna?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved Uplizna on June 11, 2020. It was the second treatment approved by the FDA for its specific indication and was developed by Horizon Therapeutics.

Approved Indications

Uplizna is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is a rare autoimmune disease that affects the central nervous system, primarily the optic nerves and spinal cord.

Regulatory Designations

During its clinical development, Uplizna received Orphan Drug designation from the FDA. This status is granted to drugs intended for the treatment of rare diseases or conditions that affect fewer than 200,000 people in the United States.

Safety and Monitoring

There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategy (REMS) programs required for Uplizna. However, the FDA-approved labeling requires healthcare providers to confirm the presence of AQP4 antibodies before initiating treatment, as the drug's efficacy has only been established in patients who are antibody-positive.

Question 11

What should I know about Uplizna and cost?

Accepted Answer

Cost Factors

The total cost of treatment with Uplizna depends on your insurance plan, your location, and the specific fees charged by the infusion center or clinic where you receive the medication.

Insurance and Prior Authorization

Because Uplizna is administered by a healthcare professional, it is usually covered under your medical insurance benefit. Most insurance plans require prior authorization, which is a process where your doctor must get approval from the insurer before the drug will be covered.

Financial Assistance Programs

The manufacturer provides support programs to help eligible patients manage the cost of Uplizna. These may include co-pay assistance for those with private insurance or patient assistance programs for individuals who are uninsured or meet certain financial criteria.

Biosimilar Status

Uplizna is a brand-name biologic medication. There are currently no biosimilars available, which are the biologic equivalent of generic drugs. This means there is no lower-cost version of the medication currently on the market.

Uplizna

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Uplizna

Hospitals.net Disclosure